MX2014015936A - Compuestos con andamio estructural de (1e,6e)-1,7-bis-(3-4-dimetox ifenil)- hepa-1,6-dieno-3,5-diona 4,4-disustituida -, su actividad biologica, y usos de los mismos. - Google Patents
Compuestos con andamio estructural de (1e,6e)-1,7-bis-(3-4-dimetox ifenil)- hepa-1,6-dieno-3,5-diona 4,4-disustituida -, su actividad biologica, y usos de los mismos.Info
- Publication number
- MX2014015936A MX2014015936A MX2014015936A MX2014015936A MX2014015936A MX 2014015936 A MX2014015936 A MX 2014015936A MX 2014015936 A MX2014015936 A MX 2014015936A MX 2014015936 A MX2014015936 A MX 2014015936A MX 2014015936 A MX2014015936 A MX 2014015936A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- cancer
- medical conditions
- disstit
- uted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000004071 biological effect Effects 0.000 title 1
- 102100032187 Androgen receptor Human genes 0.000 abstract 2
- 208000027747 Kennedy disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 2
- -1 (substituted phenyl)-propenal moiety Chemical group 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 abstract 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 abstract 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 241001303601 Rosacea Species 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002161 motor neuron Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000155 polyglutamine Polymers 0.000 abstract 1
- 108010040003 polyglutamine Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000004700 rosacea Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/525,941 US8710272B2 (en) | 2007-01-08 | 2012-06-18 | Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
| PCT/US2013/046138 WO2013192091A1 (en) | 2012-06-18 | 2013-06-17 | Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014015936A true MX2014015936A (es) | 2016-06-24 |
Family
ID=49769258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014015936A MX2014015936A (es) | 2012-06-18 | 2013-06-17 | Compuestos con andamio estructural de (1e,6e)-1,7-bis-(3-4-dimetox ifenil)- hepa-1,6-dieno-3,5-diona 4,4-disustituida -, su actividad biologica, y usos de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| EP (3) | EP3150203B1 (enExample) |
| JP (2) | JP6392752B2 (enExample) |
| KR (1) | KR102171469B1 (enExample) |
| CN (3) | CN104755076A (enExample) |
| AU (1) | AU2013277423B2 (enExample) |
| CA (1) | CA2876957C (enExample) |
| DK (1) | DK3150203T3 (enExample) |
| ES (1) | ES2775173T3 (enExample) |
| HK (1) | HK1211211A1 (enExample) |
| IN (1) | IN2015MN00131A (enExample) |
| MX (1) | MX2014015936A (enExample) |
| NZ (1) | NZ703167A (enExample) |
| SG (1) | SG11201408387YA (enExample) |
| WO (1) | WO2013192091A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018273988C1 (en) | 2017-05-26 | 2025-11-13 | Bruin Biosciences, Inc. | Chemoembolization agents |
| CN107226783B (zh) * | 2017-06-20 | 2019-07-23 | 武汉工程大学 | 一种溶酶体靶向荧光探针及其制备方法 |
| EP3508855A1 (en) * | 2018-01-05 | 2019-07-10 | Allianz Pharmascience Ltd | Method for the selection of patients and kit |
| GB2572259B (en) * | 2018-03-23 | 2022-03-30 | Merry Life Biomedical Company Ltd | Uses of curcumin derivative |
| JP2020125285A (ja) * | 2019-01-04 | 2020-08-20 | アリアンツ ファーマサイエンス リミテッド | 神経変性性障害の治療方法 |
| JP2020117489A (ja) * | 2019-01-04 | 2020-08-06 | アリアンツ ファーマサイエンス リミテッド | 脳癌の治療方法 |
| CN110183320B (zh) * | 2019-04-15 | 2021-06-11 | 四川大学 | 一类多烯二酮类抗肿瘤化合物 |
| JP7843545B2 (ja) * | 2022-04-29 | 2026-04-10 | 南京邁諾威医薬科技有限公司 | 抗アンドロゲン受容体活性を有する化合物及びその使用 |
| CN116120182A (zh) * | 2023-02-16 | 2023-05-16 | 常州大学 | 姜黄素衍生物及其合成方法和在抗雄激素受体中的应用 |
| CN116283676B (zh) * | 2023-03-24 | 2025-03-28 | 常州大学 | 一种姜黄素衍生物及其制备方法和应用 |
| CN122277382A (zh) * | 2026-05-27 | 2026-06-26 | 兰州大学第一医院 | 一种姜黄素类似物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US812408A (en) | 1905-08-19 | 1906-02-13 | Roy Ernest Dickerson | Educational device for teaching spherics. |
| US6790979B2 (en) * | 2002-04-17 | 2004-09-14 | University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
| DK2104659T3 (en) * | 2007-01-08 | 2015-11-02 | Allianz Pharmascience Ltd | Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof |
| CA2694953C (en) * | 2007-07-31 | 2015-12-01 | Androscience Corporation | Compositions including androgen receptor degradation (ard) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss |
| US20090282496A1 (en) * | 2008-04-04 | 2009-11-12 | University Of Rochester Medical Center | Androgen Receptor Related Methods for Treating Bladder Cancer |
-
2013
- 2013-06-17 ES ES16187672T patent/ES2775173T3/es active Active
- 2013-06-17 KR KR1020157000948A patent/KR102171469B1/ko active Active
- 2013-06-17 NZ NZ703167A patent/NZ703167A/en unknown
- 2013-06-17 EP EP16187672.7A patent/EP3150203B1/en active Active
- 2013-06-17 HK HK15112031.9A patent/HK1211211A1/xx unknown
- 2013-06-17 EP EP19176039.6A patent/EP3549581A3/en not_active Withdrawn
- 2013-06-17 CN CN201380040213.0A patent/CN104755076A/zh active Pending
- 2013-06-17 IN IN131MUN2015 patent/IN2015MN00131A/en unknown
- 2013-06-17 EP EP13806162.7A patent/EP2861222A4/en not_active Ceased
- 2013-06-17 CN CN201610580850.2A patent/CN106220507A/zh active Pending
- 2013-06-17 WO PCT/US2013/046138 patent/WO2013192091A1/en not_active Ceased
- 2013-06-17 AU AU2013277423A patent/AU2013277423B2/en active Active
- 2013-06-17 SG SG11201408387YA patent/SG11201408387YA/en unknown
- 2013-06-17 CN CN201910150761.8A patent/CN110279680A/zh active Pending
- 2013-06-17 JP JP2015518483A patent/JP6392752B2/ja active Active
- 2013-06-17 DK DK16187672.7T patent/DK3150203T3/da active
- 2013-06-17 MX MX2014015936A patent/MX2014015936A/es active IP Right Grant
- 2013-06-17 CA CA2876957A patent/CA2876957C/en active Active
-
2018
- 2018-05-09 JP JP2018090272A patent/JP2018135386A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3549581A3 (en) | 2020-02-19 |
| NZ703167A (en) | 2016-09-30 |
| AU2013277423B2 (en) | 2018-08-09 |
| JP6392752B2 (ja) | 2018-09-19 |
| EP3150203A1 (en) | 2017-04-05 |
| EP2861222A4 (en) | 2015-08-05 |
| EP2861222A1 (en) | 2015-04-22 |
| EP3150203B1 (en) | 2020-02-19 |
| JP2015520233A (ja) | 2015-07-16 |
| CN104755076A (zh) | 2015-07-01 |
| HK1211211A1 (en) | 2016-05-20 |
| SG11201408387YA (en) | 2015-01-29 |
| CA2876957C (en) | 2021-02-16 |
| JP2018135386A (ja) | 2018-08-30 |
| CA2876957A1 (en) | 2013-12-27 |
| CN110279680A (zh) | 2019-09-27 |
| KR102171469B1 (ko) | 2020-10-30 |
| ES2775173T3 (es) | 2020-07-24 |
| EP3549581A2 (en) | 2019-10-09 |
| KR20150023012A (ko) | 2015-03-04 |
| CN106220507A (zh) | 2016-12-14 |
| IN2015MN00131A (enExample) | 2015-10-16 |
| AU2013277423A1 (en) | 2015-01-22 |
| WO2013192091A1 (en) | 2013-12-27 |
| DK3150203T3 (da) | 2020-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3549581A3 (en) | Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | |
| Kanchi et al. | Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics | |
| JOP20200097A1 (ar) | معدل مستقبل أندروجين واستخداماته | |
| MX2010002353A (es) | Amidas heterociclicas utiles para tratamiento de cancer y psoriais. | |
| MX2009007345A (es) | Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo. | |
| MY168791A (en) | Carbamate compounds and of making and using same | |
| NZ592425A (en) | Isoindoline compounds for use in the treatment of cancer | |
| PH12012500497A1 (en) | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs | |
| WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
| MX2013004307A (es) | Derivados de arilamida como bloqueadores de ttx-s. | |
| IL221146A (en) | History of Pyridine 2,5- Two-Converted, Pharmaceutical Preparations Containing Them, and Their Use in the Preparation of Drugs for the Prevention and Treatment of Cancer | |
| TN2011000209A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| EP2004177A4 (en) | NITROFURAN COMPOUNDS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS | |
| UA101393C2 (ru) | КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ | |
| WO2009066060A3 (en) | 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use | |
| IN2015DN03219A (enExample) | ||
| MX2010003269A (es) | Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer | |
| GEP20166450B (en) | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | |
| UA101168C2 (ru) | 4-(тетразол-5-ил)хиназолиновые производные как противораковые средства | |
| WO2011058245A8 (fr) | Nouveaux derives de mannopyranoside ayant une activite anticancereuse | |
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: ANNJI PHARMACEUTICAL CO., LTD. Owner name: ALLIANZ PHARMASCIENCE LTD. |
|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: ANNJI PHARMACEUTICAL CO., LTD. |